DA5221-T1
/ Dong-A
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 20, 2025
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
(clinicaltrials.gov)
- P3 | N=174 | Active, not recruiting | Sponsor: Dong-A ST Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ Mar 2026 | Trial primary completion date: May 2025 ➔ Sep 2025
Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 04, 2024
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
(clinicaltrials.gov)
- P3 | N=162 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.
Combination therapy • New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 2
Of
2
Go to page
1